Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Personalized gene and cell therapy for Duchenne Muscular Dystrophy
Florian Barthélémy, Nicolas Wein
Neuromuscular Disorders (2018) Vol. 28, Iss. 10, pp. 803-824
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Emerging therapies for Duchenne muscular dystrophy
Theodora Markati, Maryam Oskoui, Michelle A. Farrar, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 9, pp. 814-829
Closed Access | Times Cited: 76
Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches
Yuko Shimizu‐Motohashi, Hirofumi Komaki, Norio Motohashi, et al.
Journal of Personalized Medicine (2019) Vol. 9, Iss. 1, pp. 1-1
Open Access | Times Cited: 87
Effects of exosome-mediated delivery of myostatin propeptide on functional recovery of mdx mice
Ning Ran, Xianjun Gao, Xue Dong, et al.
Biomaterials (2020) Vol. 236, pp. 119826-119826
Closed Access | Times Cited: 83
Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
F. Fortunato, Rachele Rossi, Maria Sofia Falzarano, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 4, pp. 820-820
Open Access | Times Cited: 57
CRISPR Therapeutics for Duchenne Muscular Dystrophy
Esra Erkut, Toshifumi Yokota
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1832-1832
Open Access | Times Cited: 42
The DMD gene and therapeutic approaches to restore dystrophin
F. Fortunato, Marianna Farnè, Alessandra Ferlini
Neuromuscular Disorders (2021) Vol. 31, Iss. 10, pp. 1013-1020
Closed Access | Times Cited: 42
Evaluating the potential of novel genetic approaches for the treatment of Duchenne muscular dystrophy
Vratko Himič, Kay E. Davies
European Journal of Human Genetics (2021) Vol. 29, Iss. 9, pp. 1369-1376
Open Access | Times Cited: 35
Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse
Nicolas Wein, Tatyana A. Vetter, Adeline Vulin, et al.
Molecular Therapy — Methods & Clinical Development (2022) Vol. 26, pp. 279-293
Open Access | Times Cited: 23
The complex landscape of DMD mutations: moving towards personalized medicine
Francesca Gatto, Silvia Benemei, Giulio Piluso, et al.
Frontiers in Genetics (2024) Vol. 15
Open Access | Times Cited: 5
The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
Simon Guiraud, Benjamin Edwards, Arran Babbs, et al.
Human Molecular Genetics (2019) Vol. 28, Iss. 13, pp. 2189-2200
Open Access | Times Cited: 40
Amelioration of Morphological Pathology in Cardiac, Respiratory, and Skeletal Muscles Following Intraosseous Administration of Human Dystrophin Expressing Chimeric (DEC) Cells in Duchenne Muscular Dystrophy Model
Maria Siemionow, Katarzyna Budzynska, Kristina Zalants, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 586-586
Open Access | Times Cited: 4
Natural History of Cardiomyopathy in Adult Dogs With Golden Retriever Muscular Dystrophy
Lee‐Jae Guo, Jonathan H. Soslow, Amanda K. Bettis, et al.
Journal of the American Heart Association (2019) Vol. 8, Iss. 16
Open Access | Times Cited: 32
Duchenne muscular dystrophy animal models for high-throughput drug discovery and precision medicine
Nalinda B. Wasala, Shi‐Jie Chen, Dongsheng Duan
Expert Opinion on Drug Discovery (2020) Vol. 15, Iss. 4, pp. 443-456
Open Access | Times Cited: 28
Adult stem cell sources for skeletal and smooth muscle tissue engineering
Souzan Salemi, Jenny A. Prange, Valentin Baumgartner, et al.
Stem Cell Research & Therapy (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 18
Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy
Maria Siemionow, Paulina Langa, Sonia Brodowska, et al.
Stem Cell Reviews and Reports (2022) Vol. 18, Iss. 8, pp. 2872-2892
Open Access | Times Cited: 17
Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
Ahlke Heydemann, Grzegorz Biegański, Jacek Wachowiak, et al.
Stem Cell Reviews and Reports (2023) Vol. 19, Iss. 5, pp. 1340-1359
Open Access | Times Cited: 10
Biomarkers in Duchenne Muscular Dystrophy: Current Status and Future Directions
F. Fortunato, Alessandra Ferlini
Journal of Neuromuscular Diseases (2023) Vol. 10, Iss. 6, pp. 987-1002
Open Access | Times Cited: 10
A well‐tolerated core needle muscle biopsy process suitable for children and adults
Florian Barthélémy, Jeremy D. Woods, Shirley Nieves‐Rodriguez, et al.
Muscle & Nerve (2020) Vol. 62, Iss. 6, pp. 688-698
Open Access | Times Cited: 24
Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible Treatments
Elisa Duranti, Chiara Villa
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9503-9503
Open Access | Times Cited: 9
Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration
Maria Siemionow, Grzegorz Biegański, Adam Niezgoda, et al.
Stem Cell Reviews and Reports (2023) Vol. 19, Iss. 8, pp. 2724-2740
Open Access | Times Cited: 8
Regenerative biomarkers for Duchenne muscular dystrophy
Simon Guiraud, KayE Davies
Neural Regeneration Research (2019) Vol. 14, Iss. 8, pp. 1317-1317
Open Access | Times Cited: 25
Preliminary Evidences of Safety and Efficacy of Flavonoids- and Omega 3-Based Compound for Muscular Dystrophies Treatment: A Randomized Double-Blind Placebo Controlled Pilot Clinical Trial
Clementina Sitzia, Mirella Meregalli, M. Belicchi, et al.
Frontiers in Neurology (2019) Vol. 10
Open Access | Times Cited: 25
RhoA/ROCK signalling activated by ARHGEF3 promotes muscle weakness via autophagy in dystrophic mdx mice
Jae‐Sung You, Yongdeok Kim, Soohyun Lee, et al.
Journal of Cachexia Sarcopenia and Muscle (2023) Vol. 14, Iss. 4, pp. 1880-1893
Open Access | Times Cited: 7
Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle
Giuseppe Vita, Gian Luca Vita, Olimpia Musumeci, et al.
Neurological Sciences (2019) Vol. 40, Iss. 4, pp. 671-681
Open Access | Times Cited: 22
Skeletal muscle cell transplantation: models and methods
Amber L. Mueller, Robert J. Bloch
Journal of Muscle Research and Cell Motility (2019) Vol. 41, Iss. 4, pp. 297-311
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top